

Design of polyamines-grafted starches for nucleotide analogues delivery: in vitro evaluation of the anticancer activity

Submitted by Elise Lepeltier on Wed, 12/07/2016 - 10:27

	Titre	Design of polyamines-grafted starches for nucleotide analogues delivery: in vitro evaluation of the anticancer activity
	Type de publication	Communication
	Туре	Communication par affiche dans un congrès
	Année	2016
	Langue	Anglais
	Date du colloque	12-14/12 2016
	Titre du colloque	SFNano Annual meeting 2016
	Auteur	Kanber, Erdem [1], Yamada, Hiroe [2], Loretz, Brigitta [3], Lepeltier, Elise [4], Lehr, Claus-Michael [5]
	Pays	France
	Ville	Paris
	Résumé en anglais	Nucleotide analogues are a therapeutic class really promising and currently used in clinic notably against viral infectious diseases and cancer. However, their therapeutic potential is often restricted by a poor stability in vivo, the induction of severe side effects and a limited passive intracellular diffusion due to their hydrophilicity. Polysaccharide-based polymers (e. g. starch) have considerable advantages including a lack of toxicity and absence of antigenicity. The aim of this study was to develop new cationic starches able to form complexes with nucleotide analogues: to protect them and increase their cell uptake. The material should demonstrate good biocompatibility and low cytotoxicity. Different oligoamines, (TREN, TEPA and spermine) were covalently grafted to starch: the resulting cationic starch derivatives were characterized (e.g. degree of modification) and compared in their properties to form polyplexes with ATP as a model nucleotide. Among the tested candidates, the formulation of starch-TEPA and ATP with a N/P ratio = 2 led to nanoparticles with a size of 429 nm, a PdI of 0.054 and a zeta potential of -9 mV. MTT and LDH assays on A549 cell line showed a low toxicity of this cationic starch. Confocal microscopy studies proved that the cell internalization was an incubation time and energy dependent process. Most important, starch-TEPA complexes with ddGTP (0.3 mg/mL) showed a significant biological activity on A549 cancer cells (> 90 %) compared to plain ddGTP (~ 21 %) at the same concentration, revealing a real promising system to deliver intracellularly nucleotide analogues.
	URL de la notice	http://okina.univ-angers.fr/publications/ua15249 [6]
	Lien vers le document en ligne	http://www.sfnano.fr/paris-2016/liste-des-posters/?lang=fr [7]

Liens

[1] http://okina.univ-angers.fr/publications?f%5Bauthor%5D=25245

[2] http://okina.univ-angers.fr/publications?f%5Bauthor%5D=25246

[3] http://okina.univ-angers.fr/publications?f%5Bauthor%5D=25247

[4] http://okina.univ-angers.fr/e.lepeltier/publications

[5] http://okina.univ-angers.fr/publications?f%5Bauthor%5D=25249

[6] http://okina.univ-angers.fr/publications/ua15249

[7] http://www.sfnano.fr/paris-2016/liste-des-posters/?lang=fr

Publié sur Okina (http://okina.univ-angers.fr)